Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1991 Mar;35(3):497–499. doi: 10.1128/aac.35.3.497

Susceptibility of Neisseria gonorrhoeae to cefpodoxime: determination of MICs and disk diffusion zone diameters.

T Fekete 1, J Woodwell 1, K R Cundy 1
PMCID: PMC245038  PMID: 1903910

Abstract

We studied the susceptibilities of 77 strains of Neisseria gonorrhoeae to four antibiotics: cefpodoxime, ceftriaxone, penicillin, and tetracycline. All strains were susceptible to ceftriaxone. Cefpodoxime MICs (range, 0.001 to 0.125 micrograms/ml) were parallel to and approximately four times those of ceftriaxone, and all strains will probably be considered susceptible to cefpodoxime. Disk diffusion zone diameters for cefpodoxime ranged from 35 to 57 mm. Of the strains, 32% were penicillin resistant and 51% were tetracycline resistant (MIC, greater than or equal to 2 micrograms/ml). Susceptibility measurements were consistent for disk diffusion zone diameter and MIC, with an overall agreement of 215 of 225 (96%) for ceftriaxone, penicillin, and tetracycline combined. On the basis of these in vitro data, cefpodoxime should be evaluated in the treatment of gonorrhea.

Full text

PDF
497

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baddour L. M., Gibbs R. S., Mertz G., Cocchetto D. M., Noble R. C. Clinical comparison of single-oral-dose cefuroxime axetil and amoxicillin with probenecid for uncomplicated gonococcal infections in women. Antimicrob Agents Chemother. 1989 Jun;33(6):801–804. doi: 10.1128/aac.33.6.801. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Borin M. T., Hughes G. S., Spillers C. R., Patel R. K. Pharmacokinetics of cefpodoxime in plasma and skin blister fluid following oral dosing of cefpodoxime proxetil. Antimicrob Agents Chemother. 1990 Jun;34(6):1094–1099. doi: 10.1128/aac.34.6.1094. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bryan J. P., Hira S. K., Brady W., Luo N., Mwale C., Mpoko G., Krieg R., Siwiwaliondo E., Reichart C., Waters C. Oral ciprofloxacin versus ceftriaxone for the treatment of urethritis from resistant Neisseria gonorrhoeae in Zambia. Antimicrob Agents Chemother. 1990 May;34(5):819–822. doi: 10.1128/aac.34.5.819. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Easmon C. S. Gonococcal resistance to antibiotics. J Antimicrob Chemother. 1985 Oct;16(4):409–412. doi: 10.1093/jac/16.4.409. [DOI] [PubMed] [Google Scholar]
  5. Fekete T., Serfass D. A., Lafredo S. C., Cundy K. R. Susceptibility to cephalosporins of penicillin-susceptible and penicillin-resistant strains of Neisseria gonorrhoeae from Philadelphia. Antimicrob Agents Chemother. 1989 Feb;33(2):164–166. doi: 10.1128/aac.33.2.164. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Jones R. N., Edson D. C. The identification and antimicrobial susceptibility testing of Neisseria gonorrhoeae, 1980-1987. Results from the College of American Pathologists Microbiology Surveys Program. Arch Pathol Lab Med. 1988 May;112(5):485–488. [PubMed] [Google Scholar]
  7. Jones R. N., Gavan T. L., Thornsberry C., Fuchs P. C., Gerlach E. H., Knapp J. S., Murray P., Washington J. A., 2nd Standardization of disk diffusion and agar dilution susceptibility tests for Neisseria gonorrhoeae: interpretive criteria and quality control guidelines for ceftriaxone, penicillin, spectinomycin, and tetracycline. J Clin Microbiol. 1989 Dec;27(12):2758–2766. doi: 10.1128/jcm.27.12.2758-2766.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Knapp C. C., Sierra-Madero J., Washington J. A. Antibacterial activities of cefpodoxime, cefixime, and ceftriaxone. Antimicrob Agents Chemother. 1988 Dec;32(12):1896–1898. doi: 10.1128/aac.32.12.1896. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Knapp J. S., Zenilman J. M., Biddle J. W., Perkins G. H., DeWitt W. E., Thomas M. L., Johnson S. R., Morse S. A. Frequency and distribution in the United States of strains of Neisseria gonorrhoeae with plasmid-mediated, high-level resistance to tetracycline. J Infect Dis. 1987 Apr;155(4):819–822. doi: 10.1093/infdis/155.4.819. [DOI] [PubMed] [Google Scholar]
  10. Schaadt R. D., Yagi B. H., Zurenko G. E. In vitro activity of cefpodoxime proxetil (U-76,252; CS-807) against Neisseria gonorrhoeae. Antimicrob Agents Chemother. 1990 Feb;34(2):371–372. doi: 10.1128/aac.34.2.371. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Wise R., Andrews J. M., Ashby J. P., Thornber D. The in-vitro activity of cefpodoxime: a comparison with other oral cephalosporins. J Antimicrob Chemother. 1990 Apr;25(4):541–550. doi: 10.1093/jac/25.4.541. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES